UNCY (Unicycive Therapeutics) General and Admin. Expense: $21.40 Mil (TTM As of Mar. 2026)


UNCY Unicycive Therapeutics Inc UNCY
30 GF Score
Price $5.73
! 2 Warning Signs
View Full Analysis

What is Unicycive Therapeutics General and Admin. Expense?

Unicycive Therapeutics UNCY +8.52% 30 General and Admin. Expense is $21.40 Mil as of Mar. 2026. GuruFocus rates UNCY with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Unicycive Therapeutics's General and Admin. Expense for the three months ended in Mar. 2026 was $6.83 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $21.40 Mil.

Unicycive Therapeutics General and Admin. Expense Related Terms

Unicycive Therapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Unicycive Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unicycive Therapeutics General and Admin. Expense Chart

Unicycive Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial 2.90 6.57 8.55 12.10 20.40

Unicycive Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.82 5.21 4.38 4.97 6.83
UNCY
30GF Score
Unicycive Therapeutics Inc UNCY
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Unicycive Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $21.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of $21.40 Mil mean?
Unicycive Therapeutics (UNCY) has a General and Admin. Expense of $21.40 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Unicycive Therapeutics and its competitors.
Is Unicycive Therapeutics' General and Admin. Expense too high?
Unicycive Therapeutics' current General and Admin. Expense is $21.40 Mil. Overall, Unicycive Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Unicycive Therapeutics' General and Admin. Expense compare to MDWD and ARCT?
Unicycive Therapeutics' General and Admin. Expense of $21.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Unicycive Therapeutics and its competitors. Unicycive Therapeutics's current General and Admin. Expense is $21.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unicycive Therapeutics stock overvalued right now?
Unicycive Therapeutics (UNCY) has a current General and Admin. Expense of $21.40 Mil. The current General and Admin. Expense is $21.40 Mil. Unicycive Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Unicycive Therapeutics (UNCY), the current General and Admin. Expense is $21.40 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Unicycive Therapeutics Business Description

Address 1975 W. El Camino Real, Suite 204, Mountain View, CA, USA, 94040
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
30GF Score

Get the complete analysis for UNCY

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.73
Price